The studies will be funded by the Blood Biomarker Challenge, a multi-million-pound award given by Alzheimer’s Research UK, Alzheimer’s Society, the National Institute for Health and Care Research and Gates Ventures.
Affecting more than 944,000 people in the UK, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life.
According to a recent Memory Assessment Services Audit, only 2% of people who receive a dementia diagnosis are diagnosed using tests such as ‘gold standard’ PET scans and lumbar punctures.
